Merck & Co has signed a broad-ranging deal to develop drugs based on Arvinas' PROTAC technology, which causes proteins to be broken down and removed from cells. In contrast to traditional drug ...

We sought to exploit the delicate balance between protein synthesis and degradation to treat cancer by designing a chimeric molecule, known as Protac (Proteolysis Targeting Chimeric molecule).